Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Would have been nice if he addressed what the reason for being out of stock of the material last month in todays PR. Was it because of being shipped overseas and the manufacture needed to make more or what the issue was about.
100000 for 1 split coming.
I would agree with that Slops. We need tremendous volume like a couple years back when we almost hit 1 billion in share volume in 2 days.
At least he tossed us a bone. About time
One thing which is as usual when Dr O speaks is that he said “As early as next week” which means could be weeks and not next week.
Best news in years.
But who knows. Maybe the reason they had no product left and ran out this month was because they shipped a bunch of it overseas. Hopefully next week we find out more information.
I’m still skeptical and would have believed it more if he would have put the new hire names for the key positions that were filled in June.
"I heard this time this is REAL"? From whom?
Been here before many times. ONLY TIME WILL TELL. Hope it's true.
Yes, and I heard this time this is REAL!! The agreement has already been signed and the employees have been hired.
Hopefully, we’ll now see the PPS appreciate to a few pennies, like in the past.
IMHO
Dr. Otiko also said, “We expect to make an announcement as early as next week with details of a large new international shipment of Vitastem.”
WOW, NEWS, NEWS….PRESS RELEASE!!!!
Rumors of our death have been greatly exaggerated!! LOL
IMHO
Doesn’t matter. As long as he shows sign of life. I am ok
Let the Ponzi running. We may call it whatever we want but scams also make money. We can get our money back. Let him do what he does best, we will become his cheerleaders if that’s what he wants
Sold Out Items - Any orders placed will be shipped when inventory is restocked.
Items should be back in stock by August 2024
Waiting for it
Too little too late. Now their competition has the same product and is 400% less expensive than our Ultra. :(
For Board's Information: It appears that Vitastem Ultra is back in stock, albeit at the 50% higher price. Most definitely not a big step, but, at least, it is a very minor one.
Do wish we had some great news to support some good buying then I am gone.
DB’s neighbor just bought a refrigerator so they’re good
Amitgupta looking to change zip codes on that volume! He, whatarush, and sloppy might have to share a cardboard box for shelter.
I bet he's gone already.....grifting didn't work this time.....
Looking good here!
Just keep accumulating
Obviously being sarcastic in regards to the previous poster
Oops, someone else got busted with the fake loading 😂 can’t make this up 🤣
Really how did you do that when the volume was a little over 600 k get lost and by the way you’re not a good comedian or basher buy the cheapies you’ will make money 😀
Man!!! Been looking for you for a while. Thanks for sharing but can you investigate the why of downtime? Why not more posts? Last question, what is your input about this PR you posted? Do you fully believe it?
OMG, OJC, ODL: Someone got busted with 1M!!! Caught on the lie Lmaoo Hahahahahahaha good one
Me too. I loaded 2 million shares today. Lmaooo
Grift away.....you'll sell at the next uptick like always.....
HaHaHaHaHaHaHaHaHaHa!!!!!!!!!!!!! Good one!!!!!
Yes I do target 25 cents
And you believe him? At this point, his words have no credibility.
We are currently in the strongest financial position in which we have ever been, said, Dr. Christopher Otiko, President of ViaDerma. This is the right time for us to bring on additional staff that will be in responsible
We are currently in the strongest financial position in which we have ever been, said, Dr. Christopher Otiko, President of ViaDerma. This is the right time for us to bring on additional staff that will be in responsible
In case you're wondering why Otiko has gone missing and we haven't heard a word from VDRM in months. He's on permanent vacation traveling around the world! Did a quick search and found his facebook profile. https://www.facebook.com/chris.otiko
Now it looks like he's slinging childrens books. A complete lack of disregard for the company and he has definitely broken his fiduciary duties to all the shareholders. This guy is unreal!
Yes i did.
ViaDerma Provides Highlights of Quarterly Financial ReportThe Company is expanding its staff by hiring new full-time employees
It is not a commercially available product - it seems to be a home chemistry project.
Yes all BS talk, screen does not lie, NO PURCHASE FOR ONE MILLION, TRULY BS.
LOL… No, no, no you didn’t.
Hmmm !!!. Wish Level 2 supported your claim of the one million purchase ?????
Followers
|
617
|
Posters
|
|
Posts (Today)
|
5
|
Posts (Total)
|
74427
|
Created
|
10/27/08
|
Type
|
Free
|
Moderators |
ViaDerma's proprietary transdermal delivery system allows for rapid mass transfer of the pharmaceutical active ingredient across the skin and into the body to provide immediate localized therapy.
The technology allows transfer of chemicals through the stratum corneum (outer layer of skin) with a diffusion constant which is 10,000 times higher than the diffusion constant which characterizes water movement through the stratum corneum.
This enables ViaDerma to pair almost any active ingredient with the technology and provide rapid transport of the medicine right to the site of action.
The first product is a broad spectrum tetracycline-based topical antibiotic is the only antibiotic in the world that kills bacteria both a physical and a chemical mechanism. All known antibiotics (other than ours) primarily use only a chemical mechanism of kill. The physical mechanism of kill is a key feature of what we call Rapid Active Ingredient Delivery System (RAIDS). One result of RAIDS is that tetracycline is carried in higher concentrations, more quickly, to and through the cell walls, where the tetracycline can become more effective than if conventional antibiotics were used. Conventional antibiotics require more time (usually prescribed for 5 to 7 days for best results), whereas our tetracycline-based products usually produce desirable results in 24 hours (or less) because of the RAIDS effect.
A second important result of RAIDS is that the topical antibiotic kills all harmful Gram positive and Gram negative bacteria that have been available for testing. We believe this is the world’s strongest broad-spectrum topical antibiotic available.
The potential commercial impact is immense. Drug developers believe it takes much longer for bacteria to develop drug resistance to a physical kill mechanism. This is because it is relatively easy for bacteria to change their response to a chemical threat, but it takes numerous generations for bacteria to grow a new kind of cell wall structure to respond to a physical threat.
Our novel approach to overcome drug resistance of antibiotics is designed to sustain the effectiveness of antibiotics and other topical drugs for many years. This gives new topical drug products a longer useful lifetime and therefore more commercial value. This technology, when licensed to larger pharmaceutical companies, may provide stronger incentive for the discovery and development of new antimicrobial drugs. In recent years, the dearth of new antibiotics has been largely due to the uncertain new-drug commercial lifetime which is diminished when bacteria develop immunity to that drug.
In addition the technology can be licensed to other companies to convert existing oral drugs to transdermal medications extending the profitably of the existing drug.
We are developing products in the following fields of use;
Treats all types of bacteria including MRSA, VRE and other flesh eating bacteria. Fights drug resistant bacteria. $6B/year global market.
Onychomycosis, a fungal infection of the toenails, is a major health problem. It is estimated that there are in excess of 40 million sufferers with this condition in the USA. It is a problem throughout the world. A recent European study showed that the prevalence of Onychomycosis may be as high as 26.9%. Fungal resistance can occur when the oral antifungal agents are used on a long-term basis. Topically applied antifungal drugs may work somewhat better adjunctive to surgical removal or chemical dissolution of the nail plate. Yet, this often ineffective and traumatic procedure leaves the subject without a nail for months at risk for re-infection. Given the limitations of current treatment options in this $3B market, there is a great need for a simple, nontoxic and effective alternative treatment. Estimated Global prevalence rate: 140 million.
Treats symptoms of Influenza which is a$4B/ year global market: Common
Diabetic foot wounds.
Per 3/8/18 PR: ViaDerma’s technology is currently being used in Elixr Cannabis products; Topical Balm, Topical Serum and Topical Spray. Sales have begun in Canada.
Per 12/7/17 PR: The Company has signed an MOU and will start production of its Patent Pending CBD or Cannabinoids product line. The Company would combine its two Patent pending technologies, the MMJ Patent #62466209, a patent for delivering medical marijuana / cannabis to the body by applying the medication onto the skin in an ointment base topical solution and the second Provisional patent # 62433964 for enhanced antibiotic and drug delivery for "Aqueous Topical Applications" for human and veterinary uses. The Company would combine its proprietary solutions with CBD's and other natural products that treat psoriasis, fibromyalgia for pain and other ailments.
Per 1/23/18 PR: The Company has also a licensing and distribution agreement in place with its Canadian partners to produce a CBD Topical Serum, which has a 92% absorption rate powered by ViaDerma's Patent Pending Dual Carrier Technology. The CBD and Terpene profile (enriched with specific essential oils and vitamins C, and D) is crafted to alleviate Chronic Dry Skin, Psoriasis, Eczema, Rosacea, and many other skin conditions. The serum has anti-inflammatory, anti-bacterial, and chronic pain relief properties that are absorbed by the skin and provide overall healing benefits. Sales are expected to begin in the first quarter of 2018 and are projected to generate approximately $2 million annual revenues.
The Patented Pending CBD or Cannabinoids product line. The Company would combine its two Patent pending technologies, the MMJ Patent, a patent for delivering medical marijuana / cannabis to the body by applying the medication onto the skin in an ointment base topical solution and the second Provisional patent for enhanced antibiotic and drug delivery for "Aqueous Topical Applications" for human and veterinarian uses. The Company would combine its proprietary solutions with CBD's and other natural products that treat psoriasis, fibromyalgia for pain and other ailments. The Company plans to continue to expand its (IP) "Intellectual Property Portfolio" in 2018.
CBD is a compound found in the Cannabis family of plants such as hemp. CBD is combined into our topical body care products like Elixr's Topical Balm, Serum, and Spray.
CBD is an antioxidant. Antioxidants protect our skin from damaging exposure to smoke, UV rays, and environmental pollutants. Cannabinoid receptors are located all throughout the skin, Topical CBD products interact with those receptors resulting homeostasis and healing. Studies show that CBD can help treat an array of skin conditions such as eczema, psoriasis, rosacea, and acne.
"What is Intellectual Property?" - A Publication by the World Intellectual Property Organization -
|
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |